🇺🇸 FDA
Pipeline program

BMN 351

351-202

Phase 2 small_molecule active

Quick answer

BMN 351 for Duchenne Muscular Dystrophy (DMD) is a Phase 2 program (small_molecule) at BIOMARIN PHARMACEUTICAL INC with 1 ClinicalTrials.gov record(s).

Program details

Company
BIOMARIN PHARMACEUTICAL INC
Indication
Duchenne Muscular Dystrophy (DMD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials